Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-mediated inflammation at the programmed cell death-1, programmed death-ligand-1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazama, Shingo, Morimoto, Ryota, Kimura, Yuki, Shibata, Naoki, Ozaki, Reina, Araki, Takashi, Mizutani, Takashi, Oishi, Hideo, Arao, Yoshihito, Kuwayama, Tasuku, Hiraiwa, Hiroaki, Kondo, Toru, Furusawa, Kenji, Shimokata, Tomoya, Okumura, Takahiro, Bando, Yasuko K., Ando, Yuichi, Murohara, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259377/
https://www.ncbi.nlm.nih.gov/pubmed/34229760
http://dx.doi.org/10.1186/s40959-021-00112-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259377/
https://www.ncbi.nlm.nih.gov/pubmed/34229760
http://dx.doi.org/10.1186/s40959-021-00112-z

Ejemplares similares